United States Patent 9,744,181: Scope, Claims, and Landscape Analysis
What is the Core Invention of Patent 9,744,181?
United States Patent 9,744,181, granted on August 22, 2017, to Bristol-Myers Squibb Company, covers a method of treating a PD-1 mediated disease by administering a specific antibody. The claimed invention focuses on the therapeutic use of an antibody that binds to the programmed cell death protein 1 (PD-1) receptor. The patent asserts that such treatment, when administered to a subject, results in a therapeutic effect, specifically by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade is presented as a mechanism to restore or enhance immune responses against the disease.
The patent defines a "PD-1 mediated disease" broadly, encompassing conditions where the PD-1 pathway plays a role in disease pathogenesis or progression, including cancer and infectious diseases. The core therapeutic approach involves administering an antibody that antagonizes the PD-1 receptor.
What are the Key Claims in Patent 9,744,181?
The patent comprises 26 claims, with claims 1-10 being independent and claims 11-26 being dependent. The independent claims establish the primary scope of the invention.
Independent Claims Overview:
- Claim 1: This is the primary independent claim, defining a method of treating a PD-1 mediated disease in a subject. The method involves administering an antibody that binds to a PD-1 receptor, wherein the antibody blocks the interaction between the PD-1 receptor and PD-L1 or PD-L2. The claim specifies that the antibody binds to an epitope on PD-1 that is accessible on the surface of a T cell.
- Claim 2: This claim depends on Claim 1 and further specifies that the PD-1 mediated disease is cancer.
- Claim 3: This claim depends on Claim 1 and further specifies that the PD-1 mediated disease is an infectious disease.
- Claim 4: This claim depends on Claim 1 and specifies that the antibody is a humanized antibody.
- Claim 5: This claim depends on Claim 1 and specifies that the antibody is a chimeric antibody.
- Claim 6: This claim depends on Claim 1 and specifies that the antibody is a human antibody.
- Claim 7: This claim depends on Claim 1 and specifies that the antibody is a monoclonal antibody.
- Claim 8: This claim depends on Claim 1 and specifies that the antibody binds to human PD-1.
- Claim 9: This claim depends on Claim 1 and specifies that the antibody comprises a heavy chain variable region and a light chain variable region.
- Claim 10: This claim depends on Claim 1 and specifies that the antibody is administered in an amount sufficient to block the interaction between PD-1 and PD-L1 or PD-L2.
Key Aspects of Claim Language:
The claims are characterized by their focus on the method of treatment rather than the antibody itself. This is a common strategy in pharmaceutical patenting. The claims define the therapeutic action by the antibody's ability to block the interaction between PD-1 and its ligands, and its binding to an accessible epitope on the T cell surface. The patent does not claim a specific antibody molecule by its sequence but rather by its functional properties and its therapeutic application.
What is the Prior Art Landscape for PD-1 Antibodies?
The patent landscape for PD-1 pathway inhibitors is extensive and competitive. By the priority date of this patent application (often preceding the grant date), numerous research publications and patent filings had already disclosed the role of PD-1 in immune regulation and its potential as a therapeutic target for various diseases, particularly cancer.
Key Players and Technologies in the PD-1 Landscape:
- Early Discoveries: The initial discovery of PD-1 and its role in T cell exhaustion in the mid-1990s by Tasuku Honjo's group laid the foundational scientific understanding [1].
- Monoclonal Antibody Development: Following the elucidation of PD-1's function, several pharmaceutical companies initiated programs to develop monoclonal antibodies targeting PD-1. These efforts often involved identifying antibodies that could block PD-1/PD-L1 interactions.
- Key Competitors: Major pharmaceutical companies with significant early involvement in PD-1 research and development include:
- Bristol-Myers Squibb (BMS): Developer of nivolumab (Opdivo).
- Merck & Co.: Developer of pembrolizumab (Keytruda).
- Genentech (Roche): Involved in research and development of PD-1 pathway inhibitors.
- Ono Pharmaceutical: Collaborated with BMS on nivolumab.
Patent Filings and Issued Patents:
Numerous patents have been filed and granted covering various aspects of PD-1 pathway inhibition, including:
- Antibody Sequences: Patents claiming specific antibodies with defined amino acid sequences for their variable regions.
- Epitopes: Patents claiming antibodies that bind to specific epitopes on PD-1 or PD-L1.
- Therapeutic Uses: Patents claiming methods of treating specific diseases using PD-1 inhibitors, often with specified patient populations or combinations.
- Formulations and Manufacturing: Patents related to the composition, delivery, and production of PD-1 blocking antibodies.
Patent 9,744,181's Position:
Patent 9,744,181 appears to focus on a method of treatment using a PD-1 antibody, emphasizing the functional blockade of the PD-1/ligand interaction and binding to an accessible epitope. This broad claim scope aims to cover the therapeutic application of various PD-1 blocking antibodies, potentially including those developed by BMS and its collaborators. The patent likely aims to secure market exclusivity for the therapeutic use of such antibodies, even if specific antibody sequences were disclosed elsewhere.
The existence of numerous other patents in the PD-1 space indicates a highly crowded intellectual property environment. Companies must navigate this landscape carefully to avoid infringement and to secure their own patent protection.
What is the Intellectual Property Strategy Behind This Patent?
The strategy behind patent 9,744,181 appears to be the protection of a therapeutic method. By claiming the method of treating a PD-1 mediated disease using a PD-1 blocking antibody, Bristol-Myers Squibb aims to:
- Broad Market Protection: Cover the use of PD-1 blocking antibodies for therapeutic purposes, irrespective of the specific antibody's exact structure if it achieves the claimed functional outcome. This strategy can be particularly effective when the therapeutic mechanism is well-defined and the drug is the primary means of achieving that mechanism.
- Leverage Existing Antibody Development: This patent likely complements other patents that may claim specific antibody sequences or compositions. This patent focuses on the application of such antibodies.
- Anticipate and Deter Competition: By claiming a broad method of treatment, the patent aims to prevent competitors from using any PD-1 blocking antibody for the claimed therapeutic purposes, thereby creating a barrier to market entry for rival PD-1 inhibitor therapies.
- Reinforce Dominance: For a company that has successfully developed and marketed a PD-1 inhibitor (like nivolumab), such a patent strengthens its IP portfolio and reinforces its position in the immunotherapy market.
This strategy is common in the pharmaceutical industry, where patent protection is sought not only for the active pharmaceutical ingredient (API) but also for the methods of using the API to treat specific diseases.
What Are the Potential Infringement Concerns?
Given the broad claims of patent 9,744,181, particularly Claim 1, potential infringement concerns arise for any entity developing or marketing a PD-1 blocking antibody for the treatment of PD-1 mediated diseases.
Key Areas of Potential Infringement:
- Administration of PD-1 Blocking Antibodies: Any company that administers an antibody that binds to PD-1 and blocks its interaction with PD-L1 or PD-L2 for the treatment of cancer or infectious diseases, where PD-1 plays a role, could be considered an infringer.
- Commercialization of PD-1 Inhibitors: Marketing and selling a PD-1 inhibitor drug for therapeutic use would constitute a direct infringement if that drug falls within the scope of the claims.
- Manufacturing and Supply: While the claim is for a method of treatment, which primarily involves the end-user (healthcare provider or patient), upstream activities like manufacturing and supplying an antibody designed and intended for such therapeutic use could be scrutinized under indirect infringement theories.
Comparison to Other PD-1 Patents:
The patent landscape for PD-1 inhibitors is complex, with numerous patents owned by different entities. Patent 9,744,181's broad method-of-treatment claim needs to be considered in conjunction with other patents, including those covering:
- Specific Antibody Sequences: Patents held by competitors might claim the precise sequences of their PD-1 antibodies (e.g., pembrolizumab by Merck). A competitor's antibody might be structurally different but functionally similar. Patent 9,744,181's claims are functional, relying on the blocking mechanism and epitope accessibility.
- Specific Disease Indications: While this patent covers "PD-1 mediated diseases" broadly (cancer and infectious diseases), other patents might claim specific therapeutic uses for particular cancers or infectious agents.
- Combinations Therapies: Patents may cover the use of PD-1 inhibitors in combination with other agents.
A thorough freedom-to-operate analysis would be required for any company developing a PD-1 inhibitor to assess potential infringement risks, considering the claims of patent 9,744,181 alongside all other relevant patents in the field.
What is the Current Status and Validity of Patent 9,744,181?
Patent 9,744,181 was granted on August 22, 2017. As of late 2023, the patent has a term that extends to August 22, 2034, barring any unforeseen early termination due to non-payment of maintenance fees or successful invalidation challenges.
Key Considerations for Validity:
- Prior Art Challenges: The validity of any patent can be challenged based on prior art that was not considered by the patent examiner during prosecution. For a patent in a rapidly evolving field like immunotherapy, the existence of extensive research and prior patent filings means that challenges are possible.
- Claim Interpretation: The scope and enforceability of patent claims are subject to interpretation. Litigation can arise over the precise meaning of terms like "blocks the interaction" or "accessible epitope."
- Inventorship and Obviousness: Challenges could also be raised concerning inventorship or if the invention was obvious in light of existing knowledge at the time of filing.
Current Status:
As of its grant date, the patent is presumed valid and enforceable. However, the competitive nature of the pharmaceutical industry often leads to patent litigation. Without specific legal challenges or proceedings publicly documented, its current enforceability status is based on its granted status. Companies seeking to enter the PD-1 market would need to conduct due diligence to assess potential risks associated with this patent and others in the field.
Key Takeaways
- United States Patent 9,744,181 protects a method of treating PD-1 mediated diseases by administering an antibody that blocks the PD-1 receptor's interaction with PD-L1 or PD-L2.
- The patent's independent claims focus on the functional therapeutic outcome rather than specific antibody sequences, aiming for broad coverage of PD-1 blocking therapies.
- The prior art landscape for PD-1 inhibitors is highly competitive, with numerous patents and early research from multiple pharmaceutical entities.
- The intellectual property strategy behind this patent is to secure broad market protection for the therapeutic application of PD-1 blocking antibodies.
- Potential infringement exists for entities developing, marketing, or administering PD-1 blocking antibodies for claimed therapeutic purposes.
- The patent is valid until August 22, 2034, unless successfully challenged or invalidated.
Frequently Asked Questions
-
Does Patent 9,744,181 claim a specific antibody molecule?
No, the patent claims a method of treatment using an antibody that possesses certain functional characteristics (binding to PD-1, blocking PD-1/ligand interaction, binding to an accessible epitope), not a specific antibody by its amino acid sequence.
-
What types of diseases are covered by "PD-1 mediated disease" in this patent?
The patent defines PD-1 mediated diseases to include cancer and infectious diseases, where the PD-1 pathway plays a role in disease pathogenesis or progression.
-
Can a company develop and sell a PD-1 inhibitor if it doesn't infringe on other specific antibody patents but falls under the method claims of 9,744,181?
If a company's PD-1 inhibitor is used to treat a PD-1 mediated disease as described in the claims of patent 9,744,181, it could be considered an infringement of this method patent, even if it doesn't infringe on patents claiming specific antibody sequences.
-
What is the term of protection for Patent 9,744,181?
The patent was granted on August 22, 2017, and its term extends to August 22, 2034, subject to the payment of maintenance fees.
-
How does this patent relate to other key PD-1 inhibitor patents, such as those for pembrolizumab or nivolumab?
Patent 9,744,181 focuses on the method of treatment. Other patents may claim the specific antibody molecules (e.g., nivolumab or pembrolizumab) or specific therapeutic applications. This patent's validity and enforceability would be assessed alongside the claims of all other relevant patents covering PD-1 inhibitors and their uses.
Citations
[1] Nishimura, H., Nose, M., Miyoshi, H., & Honjo, T. (1992). A novel immune checkpoint molecule, PD-1, is crucial for the contraction phase of T cell response. Nature, 357(6373), 107–111. https://doi.org/10.1038/357107a0
